337 related articles for article (PubMed ID: 37371482)
1. Chimera and Tandem-Repeat Type Galectins: The New Targets for Cancer Immunotherapy.
Ko FCF; Yan S; Lee KW; Lam SK; Ho JCM
Biomolecules; 2023 May; 13(6):. PubMed ID: 37371482
[TBL] [Abstract][Full Text] [Related]
2. Role of Galectins in Tumors and in Clinical Immunotherapy.
Chou FC; Chen HY; Kuo CC; Sytwu HK
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29389859
[TBL] [Abstract][Full Text] [Related]
3. Targeting galectin-driven regulatory circuits in cancer and fibrosis.
Mariño KV; Cagnoni AJ; Croci DO; Rabinovich GA
Nat Rev Drug Discov; 2023 Apr; 22(4):295-316. PubMed ID: 36759557
[TBL] [Abstract][Full Text] [Related]
4. Influence of Galectin-9 Treatment on the Phenotype and Function of NK-92MI Cells in the Presence of Different Serum Supplements.
Meggyes M; Nagy DU; Balassa T; Godony K; Peterfalvi A; Szereday L; Polgar B
Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439744
[TBL] [Abstract][Full Text] [Related]
5. Galectin-9 in cancer therapy.
Fujihara S; Mori H; Kobara H; Rafiq K; Niki T; Hirashima M; Masaki T
Recent Pat Endocr Metab Immune Drug Discov; 2013 May; 7(2):130-7. PubMed ID: 23514536
[TBL] [Abstract][Full Text] [Related]
6. Analysis of selected blood and immune cell responses to carbohydrate-dependent surface binding of proto- and chimera-type galectins.
Timoshenko AV; Gorudko IV; Maslakova OV; André S; Kuwabara I; Liu FT; Kaltner H; Gabius HJ
Mol Cell Biochem; 2003 Aug; 250(1-2):139-49. PubMed ID: 12962152
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of galectins in cancer: Biological challenges for their clinical application.
Laderach DJ; Compagno D
Front Immunol; 2022; 13():1104625. PubMed ID: 36703969
[TBL] [Abstract][Full Text] [Related]
8. Expression of immune checkpoint molecules of T cell immunoglobulin and mucin protein 3/galectin-9 for NK cell suppression in human gastrointestinal stromal tumors.
Komita H; Koido S; Hayashi K; Kan S; Ito M; Kamata Y; Suzuki M; Homma S
Oncol Rep; 2015 Oct; 34(4):2099-105. PubMed ID: 26239720
[TBL] [Abstract][Full Text] [Related]
9. Galectins as Emerging Glyco-Checkpoints and Therapeutic Targets in Glioblastoma.
Videla-Richardson GA; Morris-Hanon O; Torres NI; Esquivel MI; Vera MB; Ripari LB; Croci DO; Sevlever GE; Rabinovich GA
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008740
[TBL] [Abstract][Full Text] [Related]
10. Gene-expression signature of adhesion/growth-regulatory tissue lectins (galectins) in transitional cell cancer and its prognostic relevance.
Langbein S; Brade J; Badawi JK; Hatzinger M; Kaltner H; Lensch M; Specht K; André S; Brinck U; Alken P; Gabius HJ
Histopathology; 2007 Nov; 51(5):681-90. PubMed ID: 17927590
[TBL] [Abstract][Full Text] [Related]
11. Role of Galectins in Multiple Myeloma.
Storti P; Marchica V; Giuliani N
Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29258207
[TBL] [Abstract][Full Text] [Related]
12. Engineering galectin-glycan interactions for immunotherapy and immunomodulation.
Farhadi SA; Hudalla GA
Exp Biol Med (Maywood); 2016 May; 241(10):1074-83. PubMed ID: 27229902
[TBL] [Abstract][Full Text] [Related]
13. Human galectins induce conversion of dermal fibroblasts into myofibroblasts and production of extracellular matrix: potential application in tissue engineering and wound repair.
Dvořánková B; Szabo P; Lacina L; Gal P; Uhrova J; Zima T; Kaltner H; André S; Gabius HJ; Sykova E; Smetana K
Cells Tissues Organs; 2011; 194(6):469-80. PubMed ID: 21494018
[TBL] [Abstract][Full Text] [Related]
14. Galectin-3: The Impact on the Clinical Management of Patients with Thyroid Nodules and Future Perspectives.
Bartolazzi A; Sciacchitano S; D'Alessandria C
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29393868
[TBL] [Abstract][Full Text] [Related]
15. Galectins as Checkpoints of the Immune System in Cancers, Their Clinical Relevance, and Implication in Clinical Trials.
Compagno D; Tiraboschi C; Garcia JD; Rondón Y; Corapi E; Velazquez C; Laderach DJ
Biomolecules; 2020 May; 10(5):. PubMed ID: 32408492
[TBL] [Abstract][Full Text] [Related]
16. Galectin fingerprinting by immuno- and lectin histochemistry in cutaneous lymphoma.
Wollina U; Graefe T; Feldrappe S; André S; Wasano K; Kaltner H; Zick Y; Gabius HJ
J Cancer Res Clin Oncol; 2002 Feb; 128(2):103-10. PubMed ID: 11862481
[TBL] [Abstract][Full Text] [Related]
17. Decoding Strategies to Evade Immunoregulators Galectin-1, -3, and -9 and Their Ligands as Novel Therapeutics in Cancer Immunotherapy.
Lau LS; Mohammed NBB; Dimitroff CJ
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555198
[TBL] [Abstract][Full Text] [Related]
18. Targeting galectins in T cell-based immunotherapy within tumor microenvironment.
Jin QY; Li YS; Qiao XH; Yang JW; Guo XL
Life Sci; 2021 Jul; 277():119426. PubMed ID: 33785342
[TBL] [Abstract][Full Text] [Related]
19. Galectins as pivotal components in oncogenesis and immune exclusion in human malignancies.
Kapetanakis NI; Busson P
Front Immunol; 2023; 14():1145268. PubMed ID: 36817445
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells.
Sasidharan Nair V; Elkord E
Immunol Cell Biol; 2018 Jan; 96(1):21-33. PubMed ID: 29359507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
